Skip to content

Horizon Pharma misses, ups full year guidance

May 8, 2017

Horizon Pharma Plc shares HZNP, -31.10% tumbled 16% in premarket trade Monday, after the company reported a wider loss for the first quarter and said it’s buying River Vision Development Corp. for $145 million in upfront payments. Horizon said it had a net loss of $90.6 million, or a loss of 56 cents a share, in the quarter, wider than the $45.4 million loss, or 28 cents a share, posted in the year-earlier period. Adjusted per-share earnings came to 21 cents, below the FactSet consensus of 23 cents. Sales rose to $220.9 million from $204.7 million, also below the FactSet consensus of $248 million. “We generated strong first-quarter performance in our orphan and rheumatology business units, with KRYSTEXXA and RAVICTI achieving record net sales; however, our primary care business unit performed well below our expectations,” Chief Executive Timothy P. Walbert said in a statement. “The lower primary care business unit results were related to the implementation of the contracting model with pharmacy benefit managers, which has not performed in accordance with our expectations.” The company said it is buying River Vision Development Corp. and its Teprotumumab, a biologic in late-stage development for a rare eye disease. It raised its full-year sales guidance to $1.000 billion to $1.035 billion. Shares have gained 3.7% in the year to date, while the S&P 500 SPX, -0.09% has gained 7%.

http://on.mktw.net/2pd0zvV

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: